Trial Profile

International Multi-center Comparative Double-blind Randomized Clinical Trial to Evaluate Efficacy and Safety of BCD-055 (JSC BIOCAD, Russia) and Remicade in Patients With Ankylosing Spondylitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary)
Indications Ankylosing spondylitis
Focus Registrational; Therapeutic Use
Acronyms ASART-2
Sponsors Biocad

Most Recent Events

16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
21 Feb 2018 Status changed from active, no longer recruiting to completed.
17 Jun 2017 Primary endpoint (Ratio of patients with ASAS20 response after 30 weeks of therapy) has been met, according to results presented at the 18th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com